{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:23:08Z","timestamp":1792002188633,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jtct.2023.03.008","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T12:50:29Z","timestamp":1678366229000},"page":"390.e1-390.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9595-1279","authenticated-orcid":false,"given":"Jennifer","family":"Marvin-Peek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9173-1401","authenticated-orcid":false,"given":"Emily F.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Kishtagari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena V.","family":"Jayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2371-3655","authenticated-orcid":false,"given":"Bhagirathbhai","family":"Dholaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5182-3870","authenticated-orcid":false,"given":"Tae Kon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Ferrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adetola","family":"Kassim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9111-5895","authenticated-orcid":false,"given":"Michael","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.03.008_bib0001","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jtct.2023.03.008_bib0002","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1038\/sj.onc.1210302","article-title":"TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes","volume":"26","author":"Petitjean","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.jtct.2023.03.008_bib0003","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13000-021-01162-8","article-title":"TP53 mutation in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome","volume":"16","author":"Niparuck","year":"2021","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.jtct.2023.03.008_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13045-015-0139-z","article-title":"TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases","volume":"8","author":"Ok","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2023.03.008_bib0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/cncr.32566","article-title":"Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia","volume":"126","author":"Sasaki","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.03.008_bib0006","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.008_bib0007","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.03.008_bib0008","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/leu.2013.58","article-title":"Clonal diversity of recurrently mutated genes in myelodysplastic syndromes","volume":"27","author":"Walter","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.03.008_bib0009","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.03.008_bib0010","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.008_bib0011","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.008_bib0012","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.2021014472","article-title":"Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"139","author":"Grob","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.008_bib0013","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1038\/s41375-018-0351-2","article-title":"TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups","volume":"33","author":"Haase","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.03.008_bib0014","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.03.008_bib0015","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.leukres.2018.10.004","article-title":"TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome","volume":"74","author":"Kim","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.jtct.2023.03.008_bib0016","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.30203","article-title":"TP53 mutations in newly diagnosed acute myeloid leukemia: clinicomolecular characteristics, response to therapy, and outcomes","volume":"122","author":"Kadia","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.03.008_bib0017","doi-asserted-by":"crossref","first-page":"14172","DOI":"10.18632\/oncotarget.7290","article-title":"Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents","volume":"7","author":"Takahashi K","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtct.2023.03.008_bib0018","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2016.263","article-title":"The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.03.008_bib0019","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/leu.2008.173","article-title":"TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis","volume":"23","author":"Bowen","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2023.03.008_bib0020","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1200\/JCO.2016.67.3616","article-title":"Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation","volume":"34","author":"Della Porta","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.03.008_bib0021","doi-asserted-by":"crossref","first-page":"5681","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.008_bib0022","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1182\/bloodadvances.2020003508","article-title":"Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes","volume":"5","author":"Hunter","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2023.03.008_bib0023","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1080\/10428194.2020.1759051","article-title":"Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience","volume":"61","author":"Bewersdorf","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2023.03.008_bib0024","doi-asserted-by":"crossref","first-page":"e464","DOI":"10.1200\/JOP.19.00133","article-title":"Rapid donor identification improves survival in high-risk first-remission patients with acute myeloid leukemia","volume":"16","author":"Pagel","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtct.2023.03.008_bib0025","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017"},{"key":"10.1016\/j.jtct.2023.03.008_bib0026","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.2014.60.0890","article-title":"Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study","volume":"33","author":"Granfeldt \u00d8stg\u00e5rd","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.03.008_bib0027","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"de Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2023.03.008_bib0028","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.008_bib0029","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.008_bib0030","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.03.008_bib0031","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3324\/haematol.2018.205013","article-title":"Clinical implications of subclonal TP53 mutations in acute myeloid leukemia","volume":"104","author":"Prochazka","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2023.03.008_bib0032","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1182\/blood.2020006158","article-title":"TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype","volume":"136","author":"Sallman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.008_bib0033","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41409-018-0254-x","article-title":"High gastrointestinal microbial diversity and clinical outcome in graft-versus-host disease patients","volume":"53","author":"Malard","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.03.008_bib0034","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1002\/cncr.30039","article-title":"The role of the gastrointestinal microbiome in infectious complications during induction chemotherapy for acute myeloid leukemia","volume":"122","author":"Galloway-Pe\u00f1a","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2023.03.008_bib0035","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1182\/blood-2014-02-554725","article-title":"The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation","volume":"124","author":"Taur","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.008_bib0036","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2023.03.008_bib0037","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.008_bib0038","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.03.008_bib0039","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723011661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723011661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:09:08Z","timestamp":1763003348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723011661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S2666636723011661"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.03.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}